Introduction
============

Drug‐induced ventricular arrhythmia (VA) and sudden cardiac death (SCD) are rare, but severe, adverse events (AEs).^[@b1]--[@b2]^ Medications that could delay ventricular repolarization would provoke torsade de pointes, progress to VA, and consequently lead to SCD. The electrographic QT interval, which represents the time for ventricular depolarization and repolarization to occur, has been shown to be a surrogate marker for assessing the risk of torsade de pointes.^[@b3]^ Almost all medications that prolong the QT interval also block the human ether‐à‐go‐go‐related gene (*HERG*) potassium ion channel.^[@b4]^

Antipsychotics are widely used in treating patients with schizophrenia, mood disorders, and certain somatic symptoms. Several antipsychotics, primarily first‐generation antipsychotics (FGAs), were classified as torsadogenic drugs and carried a black box warning of sudden death.^[@b5]^ Second‐generation antipsychotics (SGAs), which characteristically cause less neurological adverse effects, have gradually replaced FGAs. In the past decade, concerns also have emerged about the cardiometabolic adverse effects of SGA use.^[@b6]^

Whether or not the risk of VA/SCD among SGA users is lower than that among FGA users remains inconclusive. Several studies have demonstrated that SGAs are associated with less torsadogenic risk than FGAs.^[@b7]--[@b10]^ However, such findings could not be consistently confirmed.^[@b11]--[@b13]^ These inconsistent findings were partially attributable to confounding by patient characteristics, such as baseline QT interval, cardiovascular (CV) status, and genetic factors,^[@b14]^ which usually were unmeasured in observational studies. In addition, even in the same pharmacological class, there are marked differences in the associated risk of VA/SCD across individual antipsychotics. Meta‐analyses of randomized, control trials have shown that the prolongation of QT interval varies across different SGAs.^[@b15]^ Studies using an AE reporting system database also have indicated that some SGAs have a higher torsadogenicity than others.^[@b16]--[@b17]^ Therefore, identifying antipsychotic drugs that increase the risk of VA/SCD is an important issue in clinical practice. However, owing to the low incidence of drug‐induced VA/SCD, there have been relatively few studies to date that have explored the association of torsadogenic risk with individual antipsychotic use.

In this study, we used a case‐crossover study design,^[@b18]^ which is a method to eliminate between‐person time‐invariant confounders, to investigate the risk of VA/SCD with antipsychotic exposure in a nation‐wide population‐based claims database. Furthermore, we explored the relationships between antipsychotics with the potency of hERG potassium channels blockade and the risk of VA/SCD and investigated the moderating effects of patient characteristics on such associations.

Methods
=======

Data Source
-----------

The National Health Insurance Research Database (NHIRD) is derived from the reimbursement medical claims of the National Health Insurance program in Taiwan, which launched on March 1, 1995. Since then, the NHIRD has collected demographic characteristics, disease diagnoses, and prescription records of out‐ and inpatient care claims data from Taiwan\'s National Health Insurance program enrollees representing ≈98% of the 23 million inhabitants in Taiwan.^[@b19]^ In this study, we used the data set containing subjects who had at least 1 or more prescription records for antipsychotic medications during the period from January 2000 to December 2009. This study protocol was approved by the institutional review board of the National Health Research Institutes, Taiwan.

Study Subjects
--------------

Study outcome was defined as one of the following International Classification of Diseases, Ninth Revision, Clinical Modification, diagnostic codes: paroxysmal ventricular tachycardia (427.1); ventricular fibrillation and flutter (427.4); cardiac arrest (427.5); and instantaneous death (798.1); as well as sudden death occurring in less than 24 hours from onset of symptoms (798.2). We identified patients with above‐mentioned diagnoses during the period between 2001 and 2009 through the medical records from emergency department (ED) visits or hospitalization claims data.^[@b20]--[@b21]^ Onset of VA/SCD (index date) was defined as the date of the first‐time diagnosis of VA/SCD. The exclusion criteria were described as follows: (1) patients aged less than 16 years at the index date; (2) prevalent cases who had any diagnosis of VA/SCD in 2000; (3) patients\' sex was unknown; and (4) patients who had been hospitalized within 56 days before the index date. As a result, a total of 17 718 study subjects were included for subsequent analyses. [Figure 1](#fig01){ref-type="fig"} presents a detailed flow chart regarding subject selection.

![Flow diagram of criteria for inclusion and exclusion in the present study.](jah3-4-e001568-g1){#fig01}

Exposure to Antipsychotics
--------------------------

The exposure variable was antipsychotic use, which was retrieved from the prescription records (including refills) collected in the NHIRD, which is derived from reimbursement medical claims of the National Health Insurance program in Taiwan. We defined antipsychotics (N05A) according to the Anatomic Therapeutic Chemical (ATC) classification system developed by the World Health Organization Collaborating Center.^[@b22]^ We investigated the effect of antipsychotic exposure on the risk of VA/SCD in study subjects, based on their antipsychotic exposure status. Specifically, we defined study subjects with the presence of exposure to an antipsychotic if study subjects were identified with the prescription of a particular antipsychotic at least 1 day during the case or control time period. We classified each individual antipsychotic drug examined in this study into either FGAs: chlorpromazine, clopenthixol, clothiapine, flupentixol, fluphenazine, haloperidol, loxapine, prochlorperazine, thioridazine, and trifluoperazine; or SGAs: amisulpride, aripiprazole, clozapine, olanzapine, quetiapine, risperidone, sulpiride, ziprasidone, and zotepine. Of note, lithium was classified as a mood stabilizer, rather than an antipsychotic drug, although it is coded as "N05AN01" in the ATC system.

Time‐Varying Confounding Factors
--------------------------------

Time‐varying confounders in the subsequent analyses included: health care utilization (calculated as the number of outpatient visits during the case or control periods) and concomitant medication use, including cardiometabolic drugs: antidiabetic agents (A10), anticoagulants (B01), antiarrhythmics (ATC code: C01B), digoxin and other inotropic agents (C01A), nitrates (C01D), other antihypertensives (C02), diuretics (C03), angiotensin converting‐enzyme inhibitors and angiotensin, β‐blockers (C07), calcium‐channel blockers (C08), receptor blockers (C09), statins and other lipid‐lowering agents (C10); psychiatric drugs: antidepressants (N06A), antiepileptics (N03A), anxiolytics (N05B), benzodiazepines (ATC codes: N05BA, N05CD, and N05CF); and some drugs with torsadogenic risks, including antiemetics: domperidone; and antibiotics: clarithromycin, erythromycin, halofantrine, pentamidine, and sparfloxacin.

Data Analysis
-------------

We examined the associated risk of VA/SCD with antipsychotic exposure using a case‐crossover design. In detail, given that each study patient serves as his or her own control in this case‐crossover study design, time‐invariant confounding factors, including unmeasured time‐invariant confounders, are automatically adjusted for in the subsequent analytical models. We applied conditional logistic regression models to examine the effect of antipsychotic exposure on VA/SCD. Crude and adjusted odds ratios (ORs) and the corresponding 95% confidence intervals (CIs) were computed using a pair‐matched approach to compare and evaluate the effect of antipsychotic use within the period just before the occurrence of VA/SCD (defined as the case period) with a comparable period (defined as the control period). Specifically, the case period was defined as 1 to 14 days before the index date and the control period was defined as 15 to 28 days before the index date. To explore the dose‐response effect of antipsychotic use on VA/SCD risk, we categorized average daily dose into 3 ranges: 0, \>0 to \<0.5, and ≥0.5 defined daily dose.^[@b22]^ Average daily dose was calculated by dividing cumulative doses by cumulative exposure days during the case or control periods. Furthermore, given that ventricular repolarization involves hERG potassium channels, we analyzed the relationship between the potency of the hERG potassium channel blockade and the risk of VA/SCD. The half maximal inhibitory concentration (IC~50~) of the hERG potassium channel blockade was obtained from the study by Silvestre et al.^[@b23]^ We classified antipsychotics into low and high groups, based on the median values of the potency of the hERG potassium channel blockade. Antipsychotics with an unknown defined daily dose or potency of hERG potassium channel blockade were not included in the analyses.

To determine the modifying effect of patient characteristics on VA/SCD risk, we carried out subgroup analyses stratified by various demographic and clinical characteristics of the study patients, including: age, sex, Charlson comorbidity index score,^[@b24]^ CV diseases (CVDs; yes/no), psychiatric disorders (schizophrenia, dementia, mood disorders, and others), and cumulative days of antipsychotic use in 1 year before VA/SCD, respectively. Interactions between antipsychotic exposure and each of the patient characteristics were assessed.

We tested the robustness of the results by performing several sensitivity analyses. First, given that not all SCD was caused by VA, we repeated these analyses among patients with a definitive record of VA diagnosis. Second, we repeated these analyses using 3 different time windows: 7 days (1 to 7 days before the index date as the case period and 8 to 14 days before the index date as the control period); 14 days (1 to 14 days before the index date as the case period and 14 to 28 days before the index date as the control period); and 28 days (1 to 28 days as the case period and 29 to 56 days as the control period).

We declared statistical significance using 95% CIs or a *P* value less than 0.05. All of the analyses were performed using SAS for Windows (version 9.2; SAS Institute Inc., Cary, NC).

Results
=======

A total of 17 718 patients with hospitalizations or emergency room visits for VA/SCD between 2001 and 2009 were enrolled (Figure[1](#fig01){ref-type="fig"}). Mean age at the onset of VA/SCD was 63.51 years (SD=17.64), and 45.51% of the study subjects were female. Among the study subjects, 31.35% had a history of cerebrovascular disease, 46.26% had hypertension, and 14.39% had heart failure. Details of patient demographic characteristics, medical and psychiatric comorbidity, Charlson comorbidity index score (CCIS), and cumulative days of antipsychotic use in 1 year before VA/SCD are summarized in [Table 1](#tbl01){ref-type="table"}.

###### 

Demographic and Clinical Characteristics of Subjects With Ventricular Arrhythmia and/or Sudden Cardiac Death, 2001--2009

  Characteristics                                                       N        \%
  --------------------------------------------------------------------- -------- -------
  Demographics                                                          17 718   
  Age group, y                                                                   
  17 to 64                                                              7289     41.14
  65 to 74                                                              4593     25.92
  ≧75                                                                   5836     32.94
  Gender                                                                         
  Female                                                                8063     45.51
  Male                                                                  9655     54.49
  Clinical                                                                       
  Medical comorbid disorders (yes, %)                                            
  Cerebrovascular disease                                               5554     31.35
  Chronic pulmonary disease                                             4821     27.21
  Coronary heart disease                                                3851     21.73
  Diabetes mellitus                                                     4620     26.08
  Hypertension                                                          8197     46.26
  Heart failure                                                         2549     14.39
  Conduction disorder                                                   103      0.58
  Heart valve disorders                                                 476      2.69
  Malignant neoplasm                                                    1430     8.07
  Peripheral vascular disease                                           613      3.46
  Psychiatric comorbidity (yes, %)                                               
  Dementia                                                              4922     27.78
  Mood disorder                                                         3161     17.84
  Schizophrenia and other psychosis                                     1710     9.65
  Anxiety                                                               3059     17.26
  Organic brain syndrome                                                1187     6.70
  Charlson comorbidity index score                                               
  0                                                                     3581     20.21
  1 to 2                                                                5571     31.44
  ≧3                                                                    8566     48.35
  Cumulative days of antipsychotic use in 1 year before VA and/or SCD            
  ≤7                                                                    7863     44.38
  8 to 28                                                               3385     19.10
  ≧29                                                                   6470     36.52

SCD indicates sudden cardiac death; VA, ventricular arrhythmia.

[Table 2](#tbl02){ref-type="table"} presents the effect of antipsychotic use on the risk of VA/SCD within a 14‐day window. Overall, use of antipsychotics was associated with a 1.53‐fold increased risk of VA/SCD after controlling for concomitant medication use and health system utilization. When classifying antipsychotics into FGAs and SGAs, we found that the VA/SCD risk among FGA users was slightly higher than that among SGA users (adjusted OR \[AOR\]=1.66; 95% CI, 1.43 to 1.91 for FGAs; AOR=1.36; 95% CI, 1.20 to 1.54 for SGAs). In terms of individual antipsychotics, a significantly increased risk of VA/SCD was found for clothiapine (AOR=2.16; 95% CI, 1.03 to 4.53), haloperidol (AOR=1.46; 95% CI, 1.17 to 1.83), prochlorperazine (AOR=1.69; 95% CI, 1.32 to 2.17), thioridazine (AOR=1.78; 95% CI, 1.01 to 3.15), quetiapine (AOR=1.29; 95% CI, 1.07 to 1.56), risperidone (AOR=1.39; 95% CI, 1.13 to 1.72), and sulpiride (AOR=1.26; 95% CI, 1.02 to 1.56), respectively. There was a marginal significantly increased risk for olanzapine (AOR=1.64; 95% CI, 0.98 to 2.72). Moreover, we also examined associations between the risk of definitive VA and antipsychotic use. The case number of patients with a definitive diagnosis of VA was 7769. Our results were grossly consistent with our primary analysis; however, the increased risk for clothiapine, thioridazine, quetiapine, and risperidone use was no longer statistically significant (Table S1).

###### 

Risk of Ventricular Arrhythmia and/or Sudden Cardiac Death in Relation to Current Antipsychotic Use Among 17 718 Patients

  Antipsychotic Class and Agent                            Case Period, N   Control Period, N   Crude OR                                   95% CI          Adjusted OR[\*](#tf2-2){ref-type="table-fn"}   95% CI
  -------------------------------------------------------- ---------------- ------------------- ------------------------------------------ --------------- ---------------------------------------------- ---------------
  Use of antipsychotics[\*](#tf2-1){ref-type="table-fn"}   5625             5117                *1.84* [\*](#tf2-3){ref-type="table-fn"}   1.67 to 2.03    *1.53*                                         1.38 to 1.70
  First‐generation antipsychotics                          2070             1770                *2.02*                                     1.76 to 2.33    *1.66*                                         1.43 to 1.91
  Chlorpromazine                                           248              218                 *1.98*                                     1.28 to 3.05    1.45                                           0.93 to 2.27
  Clopenthixol                                             30               25                  2.66                                       0.71 to 10.04   2.40                                           0.46 to 12.48
  Clothiapine                                              135              117                 *2.68*                                     1.33 to 5.39    *2.16*                                         1.03 to 4.53
  Flupentixol                                              400              382                 1.28                                       0.92 to 1.78    1.07                                           0.77 to 1.51
  Haloperidol                                              833              730                 *1.83*                                     1.47 to 2.27    *1.46*                                         1.17 to 1.83
  Loxapine                                                 14               14                  1.00                                       0.14 to 7.10    0.49                                           0.04 to 5.87
  Prochlorperazine                                         272              172                 *2.04*                                     1.60 to 2.61    *1.69*                                         1.32 to 2.17
  Thioridazine                                             194              173                 *2.17*                                     1.24 to 3.79    *1.78*                                         1.01 to 3.15
  Trifluoperazine                                          87               73                  *1.88*                                     1.02 to 3.44    1.37                                           0.73 to 2.57
  Second‐generation antipsychotics                         4017             3736                *1.63*                                     1.45 to 1.84    *1.36*                                         1.20 to 1.54
  Amisulpride                                              90               88                  1.14                                       0.56 to 2.34    0.94                                           0.45 to 1.96
  Aripiprazole                                             35               34                  1.14                                       0.41 to 3.15    0.90                                           0.31 to 2.59
  Clozapine                                                141              130                 *2.64*                                     1.09 to 6.38    2.03                                           0.83 to 4.94
  Olanzapine                                               245              221                 *2.01*                                     1.23 to 3.29    1.64                                           0.98 to 2.72
  Quetiapine                                               1421             1326                *1.51*                                     1.26 to 1.82    *1.29*                                         1.07 to 1.56
  Risperidone                                              1163             1066                *1.67*                                     1.36 to 2.05    *1.39*                                         1.13 to 1.72
  Sulpiride                                                1015             930                 *1.59*                                     1.29 to 1.95    *1.26*                                         1.02 to 1.56
  Ziprasidone                                              27               26                  1.20                                       0.37 to 3.93    0.80                                           0.24 to 2.67
  Zotepine                                                 154              142                 1.86                                       0.97 to 3.56    1.50                                           0.77 to 2.91

OR indicates odds ratio; SCD, sudden cardiac death; VA, ventricular arrhythmia.

Given that the case number of patients using fluphenazine, levomepromazine, methotrimeprazine, perphenazine, pimozide, pipotiazine, or paliperidone was quite small, the estimates of VA/SCD risk related to these antipsychotics are not shown.

Calculated by multivariate conditional logistic regression with adjustment for antidiabetic agents, diuretics, antithrombotic, agents, antihypertensive agents, lipid‐modifying agents, antidepressants, and number of inpatient and outpatient visits.

*P* value \<0.05 is in italics.

[Table 3](#tbl03){ref-type="table"} presents associations between antipsychotic use and risk of VA/SCD, stratified by various demographic and clinical characteristics. We found that subjects with a shorter duration of antipsychotic use had a higher risk of VA/SCD (AOR=2.11; 95% CI, 1.70 to 2.61 for cumulative days \<7 days; AOR=1.38; 95% CI, 1.19 to 1.60 for cumulative days between 8 and 28 days; AOR=1.22; 95% CI, 0.91 to 1.63 for cumulative days ≥29 days). Age, gender, CCIS, and underlying psychiatric illness had no significant modifying effect on the risk of VA/SCD. The *P* value for the interaction with antipsychotic use was 0.96 for age, 0.53 for gender, 0.34 for CCIS, 0.20 for underlying CVDs, and 0.46 for underlying psychiatric illness, individually. Similarly, Table S2 shows consistent results from the stratified analysis among patients with a definitive diagnosis of VA.

###### 

Risk of Ventricular Arrhythmia and/or Sudden Cardiac Death in Relation to Current Antipsychotic Use Among Study Patients Within the 14‐Day Window, Stratified by Demographic and Clinical Characteristics

                                                                        Case Period, N   Control Period, N   Crude OR                                   95% CI           Adjusted OR[\*](#tf3-1){ref-type="table-fn"}   95% CI
  --------------------------------------------------------------------- ---------------- ------------------- ------------------------------------------ ---------------- ---------------------------------------------- ----------------
  All patients (N=17 718)                                               5625             5117                *1.84* [\*](#tf3-2){ref-type="table-fn"}   1.67 to 2.03     *1.53*                                         1.38 to 1.70
  Subgroup analyses                                                                                                                                                                                                     
  Age group, y                                                                                                                                                                                                          
  17 to 64 (N=7289)                                                     2544             2334                *1.86*                                     1.60 to 2.18     *1.48*                                         1.25 to 1.75
  65 to 74 (N=4593)                                                     1321             1197                *1.76*                                     1.45 to 2.13     *1.55*                                         1.27 to 1.90
  ≧75 (N=5836)                                                          1760             1586                *1.88*                                     1.58 to 2.23     *1.54*                                         1.28 to 1.85
  Sex                                                                                                                                                                                                                   
  Female (N=8063)                                                       2734             2496                *1.78*                                     1.55 to 2.05     *1.60*                                         1.38 to 1.85
  Male (N=9655)                                                         2891             2621                *1.90*                                     1.65 to 2.18     *1.47*                                         1.26 to 1.70
  Charlson comorbidity index score                                                                                                                                                                                      
  0 (N=3581)                                                            1080             999                 *1.80*                                     1.41 to 2.29     1.24                                           0.95 to 1.63
  1 to 2 (N=5571)                                                       1830             1633                *2.08*                                     1.75 to 2.49     *1.68*                                         1.39 to 2.03
  ≧3 (N=8566)                                                           2715             2485                *1.73*                                     1.50 to 1.99     *1.54*                                         1.33 to 1.77
  Cardiovascular diseases[\*](#tf3-3){ref-type="table-fn"}                                                                                                                                                              
  Yes (N=11 433)                                                        3472             3162                *1.76*                                     *1.56 to 1.99*   *1.53*                                         *1.35 to 1.74*
  No (N=6285)                                                           2153             1955                *2.02*                                     *1.70 to 2.40*   *1.50*                                         *1.24 to 1.81*
  Psychiatric disorders                                                                                                                                                                                                 
  Schizophrenia (N=1710)                                                1240             1187                *1.67*                                     1.26 to 2.21     1.26                                           0.90 to 1.76
  Mood disorders (N=3161)                                               1485             1363                *1.84*                                     1.50 to 2.25     *1.44*                                         1.16 to 1.79
  Others (N=12 847)                                                     2900             2567                *1.89*                                     1.66 to 2.14     *1.61*                                         1.41 to 1.83
  Cumulative days of antipsychotic use in 1 year before VA and/or SCD                                                                                                                                                   
  \<7 (N=7863)                                                          429              173                 *2.94*                                     2.41 to 3.58     *2.11*                                         1.70 to 2.61
  8 to 28 (N=3385)                                                      1704             1496                *1.55*                                     1.36 to 1.76     *1.38*                                         1.19 to 1.60
  ≧29 (N=6470)                                                          3490             3447                *1.51*                                     1.15 to 1.98     1.22                                           0.91 to 1.63

OR indicates odds ratio; SCD, sudden cardiac death; VA, ventricular arrhythmia.

Calculated by multivariate conditional logistic regression with adjustment for antidiabetic agents, diuretics, antithrombotic, agents, antihypertensive agents, lipid‐modifying agents, antidepressants, and number of inpatient and outpatient visits.

*P* value \<0.05 is in italics.

Cardiovascular diseases included cerebrovascular disease, coronary heart diseases, heart failure, conduction disorder, hypertension, peripheral vascular disease, and heart valve disorders.

[Table 4](#tbl04){ref-type="table"} presents the associations of a defined daily dose and hERG potassium channel blockade with VA/SCD risk. We found that antipsychotics with a high hERG potassium channel blockade were associated with higher VA/SCD risk than those with a low blockade (AOR=1.24; 95% CI, 1.04 to 1.48 for high vs. low). In addition, we observed an inverse dose‐response effect (AOR=0.78; 95% CI, 0.56 to 0.70 for high vs. low).

###### 

Risk of Ventricular Arrhythmia and/or Sudden Cardiac Death in Relation to Dose and hERG Potassium Channel Blockade[\*](#tf4-1){ref-type="table-fn"}

                                                                     Case Period, N   Control Period, N   Crude OR                                   95% CI         Adjusted OR                                95% CI
  ------------------------------------------------------------------ ---------------- ------------------- ------------------------------------------ -------------- ------------------------------------------ --------------
  Ventricular arrhythmia and/or sudden cardiac death                                                                                                                                                           
  Average daily dose[\*](#tf4-2){ref-type="table-fn"}                                                                                                                                                          
  Low (\<0.5 defined daily dose)                                     3619             3179                *1.93* [\*](#tf4-4){ref-type="table-fn"}   1.73 to 2.15   *1.60* [\*](#tf4-4){ref-type="table-fn"}   1.43 to 1.80
  High (≧0.5 defined daily dose)                                     1954             1897                *1.54* [\*](#tf4-4){ref-type="table-fn"}   1.31 to 1.80   *1.25* [\*](#tf4-4){ref-type="table-fn"}   1.06 to 1.48
  High vs. low                                                                                            *0.80* [\*](#tf4-4){ref-type="table-fn"}   0.67 to 0.95   *0.78* [\*](#tf4-4){ref-type="table-fn"}   0.56 to 0.70
  hERG potassium channel blockade[\*](#tf4-3){ref-type="table-fn"}                                                                                                                                             
  Low                                                                2626             2443                *1.60* [\*](#tf4-4){ref-type="table-fn"}   1.40 to 1.83   *1.36* [\*](#tf4-4){ref-type="table-fn"}   1.18 to 1.57
  High                                                               2789             2495                *2.06* [\*](#tf4-4){ref-type="table-fn"}   1.80 to 2.35   *1.68* [\*](#tf4-4){ref-type="table-fn"}   1.47 to 1.93
  High vs. low                                                                                            *1.29* [\*](#tf4-4){ref-type="table-fn"}   1.08 to 1.53   *1.24* [\*](#tf4-4){ref-type="table-fn"}   1.04 to 1.48

hERG indicates human ether‐à‐go‐go‐related gene; OR, odds ratio.

Antipsychotics with unknown defined daily dose or pIC~50~ were not included in the analysis.

One defined daily dose of antipsychotics (mg): amisulpride (400); aripiprazole (15); chlorpromazine (300); clopenthixol (100); clozapine (300); flupentixol (6); haloperidol (8); loxapine (100); olanzapine (10); prochlorperazine (100); quetiapine (400); risperidone (5); sulpiride (800); thioridazine (300); ziprasidone (80); zotepine (200).

Blockade of hERG channels by antipsychotics (pIC~50~): amisulpride (5.00); aripiprazole (5.96); chlorpromazine (5.82); clozapine (5.85); haloperidol (7.03); olanzapine (6.64); prochlorperazine (6.11); quetiapine (5.24); risperidone (6.69); sulpiride (5.00); thioridazine (6.70); trifluoperazine (5.85); ziprasidone (6.79); zotepine (6.68).

P value \<0.05 in italics.

Furthermore, a sensitivity analysis was carried out using different time windows (specifically, 1 to 7 days for case period and 8 to 14 days for control period; 1 to 14 days for case period and 15 to 28 days for control period; and 1 to 28 days for case period and 29 to 56 days for control period, separately). No overt change was found related to the association between antipsychotic use and increased risk of VA/SCD across different time windows (Table S3). However, the difference between FGA and SGA use and risk of VA/SCD was not overt using 28‐day windows. The VA/SCD risk for olanzapine use showed a significant increase using 7‐ or 28‐day windows, but there was no significant risk associated with clothiapine use using 7‐ or 28‐day windows.

Discussion
==========

We found that antipsychotic use was associated with a 1.53‐fold increased risk of VA/SCD, after adjusting for time‐varying confounding factors. Risk of VA/SCD among FGA users might be higher than that among SGA users. Antipsychotic drugs with an increased risk of VA/SCD included haloperidol, procholorperazine, sulpiride, thioridazpine, quetiapine, and risperidione. Clothiapine and olanzapine were also associated with an increased risk of VA/SCD, although the results from the sensitivity analyses varied across different time windows. We found that the magnitude of associations was greater among patients who had shorter durations of treatment. Age, gender, underlying heart disease, and comorbid psychiatric illness did not modify relative risk of VA/SCD.

Whereas we found that risk of VA/SCD among FGA users was higher than that among SGAs users, interestingly, the difference between FGA and SGA use was more obvious when we restricted our analysis to patients with a definitive diagnosis of VA. These findings are in line with previous epidemiological studies.^[@b7]--[@b10]^ However, the underlying mechanisms for the observed findings that show SGAs to be safer than FGAs have remained largely unclear. One possible explanation might be related to the fact that public concern regarding risk of VA/SCD has risen in recent decades. Thus, SGAs with overt QT prolongation were not introduced into, or were withdrawn from, the market, such as sertindole. It should also be noted that VA/SCD risk of antipsychotic use varied markedly in the same pharmacological class. Thus, we explored VA/SCD risk of individual antipsychotic drugs. We found that most of the FGAs, such as clothiapine, haloperidol, prochlorperazine, and thioridazine, were associated with an increased risk of VA/SCD. The point estimate of VA/SCD risk for clopentixol and trifluoperazine, separately, also showed an increase, although it was not statistically significant. These findings are partially consistent with a previous study.^[@b25]^ For example, Leonard et al. compared VA/SCD risk among individual antipsychotics using a Medicaid claims database and found that haloperidol and chlorpromazine had less‐favorable cardiac safety, as compared to olanzapine. However, quetiapine was associated with a 30% decreased risk, compared to olanzapine. In addition, they also reported that risk of VA/SCD with risperidone use was similar to that with olanzapine use.^[@b25]^ Of note, we found that risk of VA/SCD with ziprasidone use was not statistically significantly, although ziprasidone was linked to QT prolongation. In our study, the number of ziprasidone user was small; therefore, the statistical power might be not enough. In addition, an open‐label, randomized, postmarketing trial, Ziprasidone Observational Study of Cardiac Outcomes (n=18 154), compared 1‐year mortality rates between ziprasidone and olanzapine. The results showed that ziprasidone was not associated with higher risk of nonsuicidal mortality than olanzapine.^[@b26]^ In the same study, the results also showed no significant difference between 2 groups in CV mortality or sudden cardiac death. Thus, risk of VA/SCD with ziprasidone use warrants more investigations.

Relative risks of VA/SCD with overall antipsychotic use in the present study were smaller than those found in previous studies, when compared to nonusers.^[@b7],[@b10]--[@b13],[@b27]--[@b29]^ Specifically, Honkola et al. suggested that use of psychotropic medication was positively associated with a 4.4‐fold increased risk of SCD during an acute coronary event among subjects in the Finnish Genetic Study of Arrhythmic Events.^[@b29]^ Straus et al., using data from Integrated Primary Care Information, reported that antipsychotic use was associated with a 3.3‐fold increased risk of SCD, as compared to risk among nonusers.^[@b28]^ Ray et al. found that the adjusted rate ratio of SCD with antipsychotic use was 2.39 using data from Tennessee Medicaid enrollees.^[@b27]^ Examining cases who die suddenly without an identified cause, Jolly et al. found that both typical and atypical antipsychotics were associated with sudden death, with an AOR of 3.94 and 4.36, respectively.^[@b11]^ Comparing to patients with glaucoma or psoriasis, Hennessy et al. found that patients with treated schizophrenia had a 1.7‐ to 3.2‐fold increase in rates of cardiac arrest and VA using 3 different Medicaid claims databases.^[@b13]^ Moreover, previous studies have found a 2‐ to 4‐fold increased risk of VA with antipsychotic use.^[@b7],[@b10],[@b12]^ It should be noted that schizophrenia itself, the major indication for antipsychotic use, was associated with SCD.^[@b30]^ Thus, it is likely that the increased risk of SCD might be partially attributable to the underlying psychiatric illness.

Using a case‐crossover design, we estimated the effect of antipsychotics on VA/SCD while perfectly controlling for underlying chronic psychiatric and CVDs. Although the estimated risks of VA/SCD in this study are smaller than those reported in previous studies, the observed results are still statistically significant.

We also found that magnitude of VA/SCD risk associated with antipsychotic use was inversely associated with duration of antipsychotic use in the preceding year. These findings indicate that increased VA/SCD risk is largely attributable to patients who only recently started taking antipsychotic drugs. Patients who were exposed to antipsychotics for more than 28 days had no excess risk of VA/SCD. These findings are compatible with those of previous studies showing that risk is highest among short‐term users.^[@b28],[@b31]^

We did not find an overtly modifying effect of patient characteristics. A slightly greater risk of VA/SCD was found in female users than their counterparts. Previous studies have suggested that females are more vulnerable to VA/SCD risk with antipsychotic use than males. The finding that QT intervals were longer in females than in males by approximately 10 msec might have contributed to this finding.^[@b32]^

Underling CVDs are important risk factors related to the development of VA/SCD. Although the relative risk of VA/SCD between patients with or without heart disease was similar in our study, it would be of interest to further investigate the absolute risk of VA/SCD among patients with and without underlying heart disease.

Of interest, we found that the risk of VA/SCD among antipsychotic users was not statistically significant among patients with schizophrenia. One possible explanation is that patients with schizophrenia tend to be long‐term users of antipsychotics; therefore, the short‐term effect on the risk of VA/SCD could not be estimated.

Blockade of hERG potassium channels was strongly associated with drug‐induced QT interval prolongation. Given that the QT interval is difficult to measure correctly, QT prolongation has been thought to be an imprecise indicator for the risk of torsades de pointes. One of the new contributions presented in this study is our exploration of the relationship between the potency of the hERG potassium channel blockade and VA/SCD risk. Importantly, we found that antipsychotics with a high potential for blocking hERG channels were associated with an increased risk of VA/SCD. This finding is compatible with those in the study by van Noord et al.^[@b31]^ Our study confirmed the role of hERG potassium channel blockade on the association between antipsychotic use and VA/SCD. Furthermore, the effect of antipsychotic use on VA/SCD was thought to be dose related.^[@b1],[@b12]^ However, we did not find a dose‐response relationship in this study. It should be noted that the dose of antipsychotics is usually slowly titrated from a low to a high dose. Given that we found that VA/SCD risk was the highest during the initial phase of antipsychotic use, the dose‐response effect of antipsychotics was not obvious in our study.

Overall, the strengths of our study include: (1) use of a case‐crossover study design, which eliminates within‐individual time‐invariant variables; (2) adjustment for concomitant medications use; (3) use of a nation‐wide representative sample with a large case number; (4) assessment of the risk of individual antipsychotics; (5) exploration of the relationship between the potency of potassium channel inhibition and VA/SCD risk; and (6) contribution of findings on the association between antipsychotic use and VA/SCD in an Asian population, which has been underinvestigated on this important matter.

However, this study also had several limitations. First, although all patients with VA/SCD who were treated antipsychotics between 2001 and 2009 were included in this study, the case number was small for assessing the risk of VA/SCD for certain antipsychotics. Thus, the results of the sensitivity analyses were slightly inconsistent. Second, though the case‐crossover design could automatically control for all time‐invariant confounders, it is likely that our results were still confounded by time‐variant factors, such as electrolyte imbalance, acute psychiatric distress, drug‐drug interaction, and changes in heart function. However, we adjusted for the concomitant use of various CV and proarrhythmic drugs, serving as proxy measures to minimize the confounding factors, in the analytical models. Third, the case‐crossover design might be vulnerable to changes in prescription patterns over time. However, the time‐trend bias would be limited owing to the fact that the examined time windows were quite short in this study. Fourth, the validation of VA/SCD in the NHIRD is a critical concern. To improve diagnostic validity, we identified VA/SCD using diagnoses from medical claims records of ED visits and hospitalizations. Of note, a previous validation study using similar algorithms reported that the positive predictive value of VA/SCD was 85.3%.^[@b20]^ Fifth, it is known that the underlying etiology of SCD is heterogeneous, including acute myocardial infarction, VA, hypertensive heart diseases, and so on.^[@b33]^ Among these, VA is one of the common causes leading to SCD. Thus, we further restricted our analysis to those only with a definitive VA diagnosis, for which our results showed gross consistency. Although VA is a heterogeneous diagnostic entity, we could not identify the subtype of VA using medical claims data. The effect of antipsychotic use on the heterogeneous type of VA warrants further investigations. Sixth, there was no information about the actual use of the prescribed antipsychotics. However, nonadherence would most likely result in nondifferentiated misclassification of the exposure, which would lead to underestimation of the actual risk. Finally, given that the data used for this study were only available between 2000 and 2009, we only excluded prevalent cases that had any diagnosis of VA/SCD in 2000. It was likely that some subjects with a history of VA/SCD before 2000 were included in this study; however, the case number would be small. Therefore, the influence of prevalent VA/SCD cases should be limited, even some study subjects with a history of VA/SCD before 2000.

Conclusions
===========

In this study, we found that antipsychotic use was associated with increased risk of VA/SCD. SGAs might be safer than FGAs in terms of risk for VA/SCD. Patients who were new antipsychotic users tended to have the highest risks. Although underlying CVD did not increase relative risk of VA/SCD with antipsychotics use, it might still increase absolute risk of VA/SCD. From the perspective of clinical implications, antipsychotic drugs should be prescribed cautiously during the initial treatment phase. A careful assessment of the risks and benefits of antipsychotic treatment is recommended, as is EKG monitoring, among those with underlying CVDs.^[@b34]^
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